NasdaqGM:MRUSBiotechs
Merus (MRUS): Reassessing Valuation After a 120% Year-to-Date Rally and Strong Multi-Year Returns
Merus (MRUS) has quietly turned into one of the stronger biotech performers this year, with the stock up more than 120% year to date as investors reprice its antibody pipeline potential.
See our latest analysis for Merus.
That kind of rerating has not come out of nowhere, with Merus enjoying a powerful 90 day share price return of 42.16% and a standout three year total shareholder return of 597.77%. This suggests momentum is still firmly building around its pipeline story.
If Merus has caught...